Pharmaceutical companies are increasingly experimenting with biomarkers in order to improve results of their clinical trials. Diagnostics companies are ideally suited to help, but pharma tends to shun them and diagnostics companies perceive that when both sides work together, the diagnostics side has less leverage. Here's how diaDexus believes it can retain clout as it works with GSK on a promising new diagnostic and therapeutic target: Lp-PLA2 for cardiovascular disease.
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
Multi-blockbuster falls short in a giant cell arteritis study.
Once hailed as a potential game changer, OG-6219 gets the axe after failing in a Phase II endometriosis-related pain trial.
4D Molecular Therapeutics has fast-tracked its Phase III trials for 4D-150 in wet AMD, with top-line data from one now expected in H1 2027 and another underway ahead of schedule. The company is also cutting a quarter of its staff as it focuses on its late-stage pipeline and to help fund the trials.
Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.
Bringing supercomputing power to bear on large-scale calculations for pharma R&D, Tokyo-based Xeureka explains the practical use of AI to empower innovation beyond the hype.
The agency gave accelerated approval to the BCMAxCD3-directed bispecific antibody, which had been the subject of an August 2024 CRL.
The gene therapy developer appointed a new president, chief medical officer and chief of staff following the closing of its acquisition by private equity firms Carlysle and SK Capital.
